Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of <i>Clostridioides difficile</i> Infection.

There was a nonsignificant trend toward more recurrences in the subgroup of patients who received FMT and were treated with non-CDI systemic antibiotics, in contrast to those who were treated with BZX (62.5% vs 27.3%: OR, 2.29; 95% CI, 0.55–9.63; P = .07) ( Table 4 ).

also in 5,406 other papers